Ultragenyx Pharmaceutical Stock Forecast, Price & News

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RARE stock has increased by 81.0% and is now trading at $82.07.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.56) by $0.74. The biopharmaceutical company had revenue of $61.71 million for the quarter, compared to the consensus estimate of $40.28 million. Ultragenyx Pharmaceutical had a negative net margin of 188.51% and a negative return on equity of 56.12%.
View Ultragenyx Pharmaceutical's earnings history.

15 brokerages have issued 12-month price objectives for Ultragenyx Pharmaceutical's stock. Their forecasts range from $64.00 to $99.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $82.38 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical saw a decline in short interest in the month of August. As of August 14th, there was short interest totaling 6,840,000 shares, a decline of 14.7% from the July 30th total of 8,020,000 shares. Based on an average daily volume of 450,900 shares, the days-to-cover ratio is presently 15.2 days. Approximately 12.2% of the company's shares are short sold.
View Ultragenyx Pharmaceutical's Short Interest.

Some companies that are related to Ultragenyx Pharmaceutical include Merck KGaA (MKGAF), Horizon Therapeutics (HZNP), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Ascendis Pharma A/S (ASND) and CureVac B.V. (CVAC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), QUALCOMM (QCOM), TG Therapeutics (TGTX) and Crispr Therapeutics (CRSP).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.48%), Federated Hermes Inc. (6.73%), Macquarie Group Ltd. (2.52%), FMR LLC (2.38%), First Trust Advisors LP (1.96%) and Bank of New York Mellon Corp (1.25%). Company insiders that own Ultragenyx Pharmaceutical stock include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Barclays PLC, First Light Asset Management LLC, UBS Group AG, Hudson Bay Capital Management LP, Macquarie Group Ltd., Prudential Financial Inc., and CHI Advisors LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical.

RARE stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Vanguard Group Inc., Nuveen Asset Management LLC, New York State Common Retirement Fund, Federated Hermes Inc., Bank of New York Mellon Corp, TD Asset Management Inc., and Two Sigma Advisers LP.
View insider buying and selling activity for Ultragenyx Pharmaceutical.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RARE stock can currently be purchased for approximately $82.07.

Ultragenyx Pharmaceutical has a market capitalization of $4.97 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]